Journal
INTERNATIONAL IMMUNOLOGY
Volume 22, Issue 1, Pages 1-6Publisher
OXFORD UNIV PRESS
DOI: 10.1093/intimm/dxp104
Keywords
adjuvant activity; CD1d; alpha-galactosylceramide; invariant V alpha 14J alpha 18; iNKT cell-targeted adjuvant therapy
Categories
Funding
- Japan Society for the Promotion of Science
Ask authors/readers for more resources
Invariant NKT (iNKT) cells bridge innate and acquired immunity and play an important role in both protective and regulatory responses. The nature of the response is dictated by the initial cytokine environment: interaction with IL-10-producing cells induces negative regulatory T(h)2/regulatory T cell-type iNKT cells, while that with IL-12-producing cells results in pro-inflammatory T(h)1-type responses. Particularly, in the anti-tumor response, iNKT cells mediate adjuvant activity by their production of IFN-gamma, which in turn activates both innate and acquired immune systems. Thus, upon activation of iNKT cells, both MHC(-) and MHC(+) tumor cells can be efficiently eliminated. On the basis of these mechanisms, iNKT cell-targeted adjuvant cell therapies have been developed and have shown great promise in initial clinical trials on cancer patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available